797 related articles for article (PubMed ID: 22943064)
61. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
62. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
63. Cardiovascular MRI in thalassemia major.
Wood JC; Noetzli L
Ann N Y Acad Sci; 2010 Aug; 1202():173-9. PubMed ID: 20712790
[TBL] [Abstract][Full Text] [Related]
64. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload.
Pepe A; Positano V; Santarelli MF; Sorrentino F; Cracolici E; De Marchi D; Maggio A; Midiri M; Landini L; Lombardi M
J Magn Reson Imaging; 2006 May; 23(5):662-8. PubMed ID: 16568436
[TBL] [Abstract][Full Text] [Related]
65. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
66. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
67. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
68. Use of fat suppression in R₂ relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients.
Papakonstantinou O; Foufa K; Benekos O; Alexopoulou E; Mademli M; Balanika A; Economopoulos N; Kelekis NL
Magn Reson Imaging; 2012 Sep; 30(7):926-33. PubMed ID: 22495242
[TBL] [Abstract][Full Text] [Related]
69. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
70. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
71. Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study.
Casale M; Meloni A; Filosa A; Cuccia L; Caruso V; Palazzi G; Gamberini MR; Pitrolo L; Putti MC; D'Ascola DG; Casini T; Quarta A; Maggio A; Neri MG; Positano V; Salvatori C; Toia P; Valeri G; Midiri M; Pepe A
Circ Cardiovasc Imaging; 2015 Aug; 8(8):e003230. PubMed ID: 26253625
[TBL] [Abstract][Full Text] [Related]
72. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
73. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V
Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
[TBL] [Abstract][Full Text] [Related]
74. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
75. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
[TBL] [Abstract][Full Text] [Related]
76. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
Galia M; Midiri M; Bartolotta V; Morabito A; Rizzo M; Mangiagli A; Malizia R; Borsellino Z; Capra M; D'Ascola DG; Magnano C; Gerardi C; Rigano P; Maggio A;
Hemoglobin; 2003 May; 27(2):63-76. PubMed ID: 12779268
[TBL] [Abstract][Full Text] [Related]
77. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
78. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
79. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
[TBL] [Abstract][Full Text] [Related]
80. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]